<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-35868" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Glycopyrrolate</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gallanosa</surname>
            <given-names>Ariel</given-names>
          </name>
          <aff>Michigan State University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Stevens</surname>
            <given-names>Joshua B.</given-names>
          </name>
          <aff>Augusta University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Quick</surname>
            <given-names>Judy</given-names>
          </name>
          <aff>Aurora Vista Del Mar</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ariel Gallanosa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Joshua Stevens declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Judy Quick declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-35868.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Glycopyrrolate, also known as glycopyrronium, is an anticholinergic drug. Glycopyrrolate has been widely used as a preoperative medication to inhibit salivary gland and respiratory secretions. The most frequent reasons for administering anticholinergics include producing an antisialagogue effect, creating a sedative and amnesic effect, and preventing reflex bradycardia. Glycopyrrolate is among the more common anticholinergic medications. It is used perioperatively as a muscarinic receptor antagonist. This activity outlines the indications, mechanism of action, dosing, important adverse effects, contraindications, monitoring, the toxicity of glycopyrrolate. It increases practitioners' knowledge regarding how to approach and use this medication and monitor it effectively to drive better patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain the mechanism of action of glycopyrrolate.</p></list-item><list-item><p>Identify the indications for using glycopyrrolate on a patient.</p></list-item><list-item><p>Review the necessary monitoring that must take place when utilizing glycopyrrolate.</p></list-item><list-item><p>Outline interprofessional team strategies for improving care coordination and communication to advance improved outcomes using glycopyrrolate when indicated.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=35868&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=35868">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-35868.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Glycopyrrolate, also known as glycopyrronium,&#x000a0;is an&#x000a0;anticholinergic drug. It is a synthetically created quaternary amine with pyridine and a cyclopentane moiety within the compound's structure. Glycopyrrolate&#x000a0;has been widely used as a preoperative medication to inhibit salivary gland and respiratory secretions. The most frequent reasons for administering anticholinergics&#x000a0;include producing an antisialagogue effect, creating a sedative and amnesic effect, and preventing reflex bradycardia. Anticholinergics are not predictably effective in increasing gastric fluid pH or decreasing gastric fluid volume. Glycopyrrolate is&#x000a0;among the most commonly used anticholinergic medications.</p>
        <list list-type="bullet">
          <list-item>
            <p>It is used perioperatively as a muscarinic receptor antagonist.<xref ref-type="bibr" rid="article-35868.r1">[1]</xref><xref ref-type="bibr" rid="article-35868.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>The topical formulation of glycopyrrolate is indicated to treat primary axillary hyperhidrosis in nine and older patients.<xref ref-type="bibr" rid="article-35868.r3">[3]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>It is also helpful to reduce severe or chronic drooling in pediatric patients with neurologic conditions, such as cerebral palsy.&#x000a0;The&#x000a0;intravenous formulation&#x000a0;of glycopyrrolate classically works to reverse vagal reflexes and bradycardia intraoperatively and reverse the&#x000a0;muscarinic effects of cholinergic agents such as neostigmine or pyridostigmine.<xref ref-type="bibr" rid="article-35868.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Glycopyrrolate&#x000a0;may be administered to reverse the neuromuscular blockade due to nondepolarizing muscle relaxants postoperatively and is frequently used in conjunction&#x000a0;with neostigmine, a cholinesterase inhibitor.<xref ref-type="bibr" rid="article-35868.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Various oral inhalation formulations of glycopyrrolate are indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).<xref ref-type="bibr" rid="article-35868.r6">[6]</xref><xref ref-type="bibr" rid="article-35868.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>Other commonly used anticholinergics include atropine and scopolamine. Most frequently, clinicians use glycopyrrolate to reduce pharyngeal, tracheal, bronchial, and sialagogue effects preoperatively;&#x000a0;decreased secretions are the desired effect during anesthesia when a tracheal tube is in place. A blockade of reflexive vagal cardiac inhibition reflexes during intubation and anesthetic induction may also occur.</p>
      </sec>
      <sec id="article-35868.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Glycopyrrolate's primary mechanism of action is the blockage of acetylcholine's effects at the parasympathetic sites in various tissues. This blockage primarily occurs in the central nervous system, smooth muscle, and secretory glands. It also reduces the rate of salivation by preventing the stimulation of the acetylcholine receptors themselves. Glycopyrrolate does not cross the blood-brain barrier or the placenta. It has a slower diffusion rate relative to other anticholinergic drugs such as atropine&#x000a0;and scopolamine.<xref ref-type="bibr" rid="article-35868.r8">[8]</xref><xref ref-type="bibr" rid="article-35868.r9">[9]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Glycopyrrolate exhibits onset of action within 1 minute when given intravenously and an elimination half-life of approximately 50 minutes. Glycopyrrolate undergoes urinary excretion and elimination. It differs from atropine in being a quaternary amine and has both cyclopentane and pyridine moieties in the compound.<xref ref-type="bibr" rid="article-35868.r10">[10]</xref>&#x000a0;&#x000a0;Glycopyrrolate has a 2 to the 4-hour duration of action after intravenous administration, while atropine has 30 minutes.</p>
      </sec>
      <sec id="article-35868.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Glycopyrrolate administration can be intravenous, intramuscular, oral, or topical.</p>
        <list list-type="bullet">
          <list-item>
            <p>Glycopyrrolate for injection comes packaged as a solution of 0.2 mg/mL. Before intravenous administration, inspect the syringe to ensure no particulate matter. Intramuscular or intravenous administration requires no dilution and should be at 0.2 mg over 1 to 2 minutes. Additionally, it may be administered via the tubing of a running intravenous infusion of a compatible solution.<xref ref-type="bibr" rid="article-35868.r11">[11]</xref>&#x000a0;Storage of the drug should be in a cool, dry area protected from light before administration. Promptly discard unused solution as it is unstable at a pH greater than 6. The typical dose of glycopyrrolate is one-half that of atropine. For instance, the premedication dose is 0.005 to 0.01 mg/kg up to 0.2 to 0.3 mg in adults.</p>
          </list-item>
          <list-item>
            <p>Oral tablets are available in 1 mg, 1.5 mg, and 2 mg strength and oral solution is available in 1mg/5mL strength. The starting dose is 1 to 2 mg twice a day and titrated upward gradually based on patient response to the treatment.<xref ref-type="bibr" rid="article-35868.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>The topical formulation is available as a single-use cloth pre-moistened with a 2.4% glycopyrronium solution. It is used no more than once every 24 hours on both underarms.<xref ref-type="bibr" rid="article-35868.r13">[13]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Inhalation formulation available as the dry powder inhaler 15.6 mcg capsule twice daily and as the nebulization solution of one 25 mcg vial inhaled twice daily.<xref ref-type="bibr" rid="article-35868.r14">[14]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Population</bold>
</p>
        <p><bold>Pregnancy Considerations:</bold> Glycopyrrolate in usual doses does not influence fetal heart rate or fetal heart rate variability to a significant extent. After parenteral administration, there&#x000a0;is&#x000a0;a low concentration of glycopyrrolate in umbilical venous and arterial blood and the amniotic fluid. Glycopyrrolate does not seem to penetrate through the placental barrier significantly. As animal reproduction studies are not consistently predictive of human response, this drug should be used during pregnancy only if needed. In general, because of limited data in human pregnancy studies, both atropine and glycopyrrolate are considered acceptable anticholinergics, and usage varies based on the clinician's preference.<xref ref-type="bibr" rid="article-35868.r15">[15]</xref></p>
        <p><bold>Breastfeeding Considerations:</bold>&#x000a0;Glycopyrrolate is a quaternary ammonium compound; it is not likely to be absorbed and reach the infant's bloodstream, particularly when given by inhalation or applied topically on the skin. Long-term oral use of glycopyrrolate might reduce milk production or milk letdown, but a single dose is unlikely to interfere with breastfeeding. Observe for signs of decreased lactation (e.g., insatiety, poor weight gain).<xref ref-type="bibr" rid="article-35868.r10">[10]</xref></p>
        <p><bold>Patients with Renal Impairment:</bold> According to product labeling, dose adjustment might be necessary. Clinicain should exercise caution when using glycopyrrolate in patients with renal impairment.&#x000a0;</p>
        <p><bold>Patients with Hepatic Impairment:</bold> According to product labeling, information on patients with hepatic impairment is unavailable. Use with caution.</p>
        <p>Pediatrics Patients: Usage should generally&#x000a0;be avoided in neonates. A&#x000a0;hyperexcitability reaction can potentially occur with higher than recommended dosages; use with caution.</p>
      </sec>
      <sec id="article-35868.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse reactions after glycopyrrolate administration may include anticholinergic symptoms such as mydriasis, hyperthermia, tachycardia, and cardiac arrhythmia. They may also include blurred vision, constipation, cycloplegia, dry mouth, dry skin, flushing, photophobia, urinary retention, and xerophthalmia.<xref ref-type="bibr" rid="article-35868.r2">[2]</xref><xref ref-type="bibr" rid="article-35868.r16">[16]</xref></p>
        <p>Glycopyrrolate may affect the patient's ability to perform tasks requiring mental alertness. In addition, the medication may induce drowsiness&#x000a0;or blurred vision, which is exacerbated by the consumption of alcohol. Usage also requires close monitoring in patients with hepatic impairment. For example, patients may not be able to&#x000a0;operate heavy machinery safely.</p>
        <p>Use with discretion&#x000a0;in patients with autonomic neuropathy or hyperthyroidism. Heat prostration can occur in the presence of fever, high ambient temperature, or physical exercise. Take caution to avoid this effect by limiting or discontinuing usage with exercise or in situations with elevated ambient temperatures.</p>
        <p>Patients under the age of 12 with pediatric spastic paralysis are more likely to exhibit an increased anticholinergic response, which elevates the risk for unwanted effects.<xref ref-type="bibr" rid="article-35868.r17">[17]</xref></p>
      </sec>
      <sec id="article-35868.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Glycopyrrolate is contraindicated in patients with hypersensitivity to glycopyrronium, excipients, or other ingredients in the anticholinergic class. The following is a list of medical conditions that would preclude the use of anticholinergic therapy, categorized by the system:</p>
        <list list-type="bullet">
          <list-item>
            <p>Ophthalmic: angle-closure glaucoma<xref ref-type="bibr" rid="article-35868.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p>Cardiovascular: mitral stenosis and cardiovascular instability in acute hemorrhage<xref ref-type="bibr" rid="article-35868.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <p>Gastrointestinal: hiatal hernia, gastrointestinal obstruction, paralytic ileus, reflux esophagitis, severe ulcerative colitis, toxic megacolon, intestinal atony in elderly or debilitated patients<xref ref-type="bibr" rid="article-35868.r20">[20]</xref><xref ref-type="bibr" rid="article-35868.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>Neuromuscular: myasthenia gravis<xref ref-type="bibr" rid="article-35868.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Urologic: obstructive uropathy<xref ref-type="bibr" rid="article-35868.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>Using solid oral formulations of potassium chloride needs close monitoring if considering coadministration with glycopyrrolate.<xref ref-type="bibr" rid="article-35868.r24">[24]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-35868.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Glycopyrronium reduces the body's ability to sweat. Therefore,&#x000a0;it&#x000a0;may cause hyperthermia&#x000a0;and heat stroke&#x000a0;in hot environments. Other observed adverse effects include dry mouth, difficulty urinating, headaches, diarrhea, and constipation.&#x000a0;Monitor heart rate and maintain adequate hydration to avoid adverse events.</p>
        <p>A dose adjustment may be necessary if urinary retention occurs. Existing renal impairment may be further complicated. In the general population, usage may increase the risk of confusion, hallucinations, and anticholinergic effects.<xref ref-type="bibr" rid="article-35868.r25">[25]</xref></p>
        <p>Use glycopyrrolate with caution in patients with a hiatal hernia&#x000a0;and reflux esophagitis. It can worsen prostatic hyperplasia symptoms and/or bladder neck destruction as it may increase urinary retention.&#x000a0;In ulcerative colitis cases, a high dose may inhibit intestinal motility and&#x000a0;worsen toxic megacolon or ileus symptoms. Glycopyrrolate administration&#x000a0;is contraindicated in patients with ulcerative colitis. Since gastrointestinal motility may decline, constipation or intestinal pseudo-obstruction may occur. If the latter condition arises, it may result in pain from abdominal distention, nausea, or vomiting. If intestinal&#x000a0;obstruction of any type is suspected, it is imperative to&#x000a0;discontinue use and simultaneously reevaluate. Symptoms presenting as diarrhea, particularly in patients who have undergone bowel resections of the ileum or colon, warrant a lower threshold for clinical suspicion. When an&#x000a0;obstruction is suspected, or if the patient has&#x000a0;diarrhea, promptly discontinue treatment.<xref ref-type="bibr" rid="article-35868.r11">[11]</xref></p>
        <p>Because of its quaternary structure, glycopyrrolate cannot cross the blood-brain barrier and is almost devoid of the central nervous system and ophthalmic activity. Potent inhibition of salivary gland and respiratory tract secretions is the primary rationale for using glycopyrrolate as a premedication. Heart rate usually increases after intravenous&#x000a0;administration but not intramuscular.<xref ref-type="bibr" rid="article-35868.r2">[2]</xref></p>
      </sec>
      <sec id="article-35868.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Acute toxicity with glycopyrrolate is secondary to an extension of the pharmacologic effects on the muscarinic cholinergic receptors. Muscarinic receptor sites are located in the brain's cerebral cortex, thalamus, hippocampus, and reticular activating system. They are also present in the postganglionic parasympathetic nervous system and other sites like sweat glands. Anticholinergic agents block the effects of acetylcholine by competitively binding and blocking muscarinic receptors.</p>
        <p>
<bold>Central Nervous System Toxicity</bold>
</p>
        <p>CNS toxicity is also called a central anticholinergic syndrome, as central nervous system toxicity can be an undesirable side effect of any anticholinergic medication. It manifests as delirium or prolonged somnolence after anesthesia. While this is more likely to occur with scopolamine than atropine, the incidence should be low with the administration of proper dosages. However, elderly patients may be uniquely susceptible. Glycopyrrolate is less likely to cause this condition than other anticholinergic medications because it does not cross the blood-brain barrier.<xref ref-type="bibr" rid="article-35868.r26">[26]</xref></p>
        <p>
<bold>Tachycardia</bold>
</p>
        <p>The most likely response after intramuscular administration of atropine, glycopyrrolate, or scopolamine for premedication is an increase in heart rate, indicating a weak cholinergic antagonist effect of these drugs.</p>
        <p>
<bold>Treatment</bold>
</p>
        <p>According to product labeling, a quaternary ammonium anticholinesterase such as neostigmine (which does not cross the blood-brain barrier) can be given to combat peripheral anticholinergic effects parenterally in increments of 0.25 mg in adults. It may be repeated every five to ten minutes until anticholinergic overactivity is reversed or up to a maximum of 2.5 mg.&#x000a0;If CNS symptoms (e.g., restlessness, excitement, psychotic behavior, convulsions) are present, physostigmine (which does cross the blood-brain barrier) should be administered. Physostigmine 0.5 to 2 mg can be administered intravenously and repeated up to 5 mg in adults. To combat hypotension, administer IV fluids and pressor agents and supportive care.</p>
      </sec>
      <sec id="article-35868.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Glycopyrrolate is a frequently prescribed agent by the nurse practitioner, primary care provider, anesthesiologist, and internist. However, all healthcare workers who prescribe this agent should be aware of its potential adverse effects.&#x000a0;Glycopyrronium may cause hyperthermia&#x000a0;and heat stroke&#x000a0;in hot environments as it reduces the body's ability to sweat. Clinicians should monitor liver function tests in patients with hepatic impairment. Nursing staff should monitor and inform the prescriber if urinary retention occurs and existing renal impairment worsens. The use&#x000a0;of glycopyrrolate in the general population may increase the risk&#x000a0;of&#x000a0;confusion, hallucinations, and other anticholinergic effects.<xref ref-type="bibr" rid="article-35868.r25">[25]</xref>&#x000a0;Before administering glycopyrrolate therapy, nurses should counsel patients for common adverse effects&#x000a0;like dry mouth, difficulty urinating, headaches, diarrhea, and constipation. Pharmacists should verify the dose and possible drug-disease interactions. Pharmacists should warn the patient that the medication may induce drowsiness&#x000a0;or blurred vision, which is exacerbated by alcohol consumption. As health care team members, all MDs, DOs, PAs, NPs, nursing staff, and pharmacists should collaborate to improve care coordination and communicate to advance better outcomes using glycopyrrolate when indicated.</p>
      </sec>
      <sec id="article-35868.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=35868&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=35868">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/35868/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=35868">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-35868.s11">
        <title>References</title>
        <ref id="article-35868.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reisner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pearle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kerwin</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Darken</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.</article-title>
            <source>Int J Chron Obstruct Pulmon Dis</source>
            <year>2018</year>
            <volume>13</volume>
            <fpage>1965</fpage>
            <page-range>1965-1977</page-range>
            <pub-id pub-id-type="pmid">29950826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chabicovsky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Winkler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Soeberdt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kilic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Masur</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Abels</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology, toxicology and clinical safety of glycopyrrolate.</article-title>
            <source>Toxicol Appl Pharmacol</source>
            <year>2019</year>
            <month>May</month>
            <day>01</day>
            <volume>370</volume>
            <fpage>154</fpage>
            <page-range>154-169</page-range>
            <pub-id pub-id-type="pmid">30905688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Albornoz L&#x000f3;pez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arias Rico</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Torres Degay&#x000f3;n</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gago S&#x000e1;nchez</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Formulation of topical glycopyrrolate for hyperhidrosis].</article-title>
            <source>Farm Hosp</source>
            <year>2008</year>
            <season>Nov-Dec</season>
            <volume>32</volume>
            <issue>6</issue>
            <fpage>362</fpage>
            <page-range>362-3</page-range>
            <pub-id pub-id-type="pmid">19232224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fuchs-Buder</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hofmockel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Geldner</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Diefenbach</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ulm</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Blobner</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[The use of neuromuscular monitoring in Germany].</article-title>
            <source>Anaesthesist</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>52</volume>
            <issue>6</issue>
            <fpage>522</fpage>
            <page-range>522-6</page-range>
            <pub-id pub-id-type="pmid">12835874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nicolardot</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Engelman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Coeckelenbergh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jungels</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baurain</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Neostigmine accelerates recovery from moderate mivacurium neuromuscular block independently of train-of-four count at injection: a randomised controlled trial.</article-title>
            <source>Br J Anaesth</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>121</volume>
            <issue>2</issue>
            <fpage>497</fpage>
            <page-range>497-499</page-range>
            <pub-id pub-id-type="pmid">30032892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <article-title>Nebulized glycopyrrolate (Lonhala Magnair) for COPD.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2018</year>
            <month>Apr</month>
            <day>23</day>
            <volume>60</volume>
            <issue>1543</issue>
            <fpage>72</fpage>
            <pub-id pub-id-type="pmid">29667949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martinez</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Rabe</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Fabbri</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Rennard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Sethi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Spangenthal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gottschlich</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Rodriguez-Roisin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arora</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Siler</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Darken</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Maes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Golden</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Orevillo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Reisner</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.</article-title>
            <source>Chest</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>151</volume>
            <issue>2</issue>
            <fpage>340</fpage>
            <page-range>340-357</page-range>
            <pub-id pub-id-type="pmid">27916620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Both</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Moreno-Gonz&#x000e1;lez</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Reyes</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Dernovics</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Monitoring the degradation of atropine and scopolamine in soil after spiking with naturally contaminated organic millet.</article-title>
            <source>Sci Total Environ</source>
            <year>2018</year>
            <month>Jun</month>
            <day>01</day>
            <volume>625</volume>
            <fpage>1088</fpage>
            <page-range>1088-1092</page-range>
            <pub-id pub-id-type="pmid">29996405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gruber</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Scopalamine-induced anterograde amnesia.</article-title>
            <source>Int J Neuropharmacol</source>
            <year>1967</year>
            <month>May</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>187</fpage>
            <page-range>187-90</page-range>
            <pub-id pub-id-type="pmid">6068339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <chapter-title>Glycopyrrolate</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2022</year>
            <month>11</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">30000540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sridharan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sivaramakrishnan</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological interventions for treating sialorrhea associated with neurological disorders: A mixed treatment network meta-analysis of randomized controlled trials.</article-title>
            <source>J Clin Neurosci</source>
            <year>2018</year>
            <month>May</month>
            <volume>51</volume>
            <fpage>12</fpage>
            <page-range>12-17</page-range>
            <pub-id pub-id-type="pmid">29475576</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walling</surname>
                <given-names>HW</given-names>
              </name>
            </person-group>
            <article-title>Systemic therapy for primary hyperhidrosis: a retrospective study of 59 patients treated with glycopyrrolate or clonidine.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>66</volume>
            <issue>3</issue>
            <fpage>387</fpage>
            <page-range>387-92</page-range>
            <pub-id pub-id-type="pmid">21820204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olamiju</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Panse</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>McFerren</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic treatment of multiple eccrine hidrocystomas with topical glycopyrronium tosylate 2.4% solution.</article-title>
            <source>JAAD Case Rep</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>369</fpage>
            <page-range>369-371</page-range>
            <pub-id pub-id-type="pmid">32258325</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tashkin</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease.</article-title>
            <source>Int J Chron Obstruct Pulmon Dis</source>
            <year>2018</year>
            <volume>13</volume>
            <fpage>1873</fpage>
            <page-range>1873-1888</page-range>
            <pub-id pub-id-type="pmid">29928118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shin</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Anesthetic Management of the Pregnant Patient: Part 2.</article-title>
            <source>Anesth Prog</source>
            <year>2021</year>
            <month>Jun</month>
            <day>01</day>
            <volume>68</volume>
            <issue>2</issue>
            <fpage>119</fpage>
            <page-range>119-127</page-range>
            <pub-id pub-id-type="pmid">34185861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varssano</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rothman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lazar</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The mydriatic effect of topical glycopyrrolate.</article-title>
            <source>Graefes Arch Clin Exp Ophthalmol</source>
            <year>1996</year>
            <month>Mar</month>
            <volume>234</volume>
            <issue>3</issue>
            <fpage>205</fpage>
            <page-range>205-7</page-range>
            <pub-id pub-id-type="pmid">8720721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Shave</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Coulson</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rosser-Stanford</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Eves</surname>
                <given-names>ND</given-names>
              </name>
            </person-group>
            <article-title>Influence of vagal control on sex-related differences in left ventricular mechanics and hemodynamics.</article-title>
            <source>Am J Physiol Heart Circ Physiol</source>
            <year>2018</year>
            <month>Sep</month>
            <day>01</day>
            <volume>315</volume>
            <issue>3</issue>
            <fpage>H687</fpage>
            <page-range>H687-H698</page-range>
            <pub-id pub-id-type="pmid">29856652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jaroudi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fadi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Farah</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>El Mollayess</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Glycopyrrolate induced bilateral angle closure glaucoma after cervical spine surgery.</article-title>
            <source>Middle East Afr J Ophthalmol</source>
            <year>2013</year>
            <season>Apr-Jun</season>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>182</fpage>
            <page-range>182-4</page-range>
            <pub-id pub-id-type="pmid">23741140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bali</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Mirakhur</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Glycopyrrolate, atropine and hyoscine in mixture with neostigmine for reversal of neuromuscular block following closed mitral valvotomy.</article-title>
            <source>Acta Anaesthesiol Scand</source>
            <year>1980</year>
            <month>Aug</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>331</fpage>
            <page-range>331-5</page-range>
            <pub-id pub-id-type="pmid">7468122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r20">
          <label>20</label>
          <element-citation publication-type="book">
            <chapter-title>Glycopyrrolate</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>7</month>
            <day>7</day>
            <pub-id pub-id-type="pmid">31643554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hunt</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Yates</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Vega</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Heidel</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Buehler</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Effects on Postoperative Gastrointestinal Motility After Neuromuscular Blockade Reversal With Sugammadex Versus Neostigmine/Glycopyrrolate in Colorectal Surgery Patients.</article-title>
            <source>Ann Pharmacother</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>54</volume>
            <issue>12</issue>
            <fpage>1165</fpage>
            <page-range>1165-1174</page-range>
            <pub-id pub-id-type="pmid">32468846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hindmarsh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Everett</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hindmarsh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pickard</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Glycopyrrolate and the Management of "Death Rattle" in Patients with Myasthenia Gravis.</article-title>
            <source>J Palliat Med</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>10</issue>
            <fpage>1408</fpage>
            <page-range>1408-1410</page-range>
            <pub-id pub-id-type="pmid">31976808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Low</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Escobar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baquero</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Glycopyrrolate and Post-Operative Urinary Retention: A Narrative Review.</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>Nov</month>
            <day>08</day>
            <volume>12</volume>
            <issue>11</issue>
            <fpage>e11379</fpage>
            <pub-id pub-id-type="pmid">33312781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alsop</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Rollins</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Tolman</surname>
                <given-names>KG</given-names>
              </name>
            </person-group>
            <article-title>The effects of five potassium chloride preparations on the upper gastrointestinal mucosa in healthy subjects receiving glycopyrrolate.</article-title>
            <source>J Clin Pharmacol</source>
            <year>1984</year>
            <season>May-Jun</season>
            <volume>24</volume>
            <issue>5-6</issue>
            <fpage>235</fpage>
            <page-range>235-9</page-range>
            <pub-id pub-id-type="pmid">6747020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scott</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Langdon</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Moorthy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Purkayastha</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Prospective Risk Factor Analysis for the Development of Post-operative Urinary Retention Following Ambulatory General Surgery.</article-title>
            <source>World J Surg</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>42</volume>
            <issue>12</issue>
            <fpage>3874</fpage>
            <page-range>3874-3879</page-range>
            <pub-id pub-id-type="pmid">29947990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35868.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Misal</surname>
                <given-names>US</given-names>
              </name>
              <name>
                <surname>Joshi</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Shaikh</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Delayed recovery from anesthesia: A postgraduate educational review.</article-title>
            <source>Anesth Essays Res</source>
            <year>2016</year>
            <season>May-Aug</season>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>164</fpage>
            <page-range>164-72</page-range>
            <pub-id pub-id-type="pmid">27212741</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
